51 Gerok W,Hepatologie.Urban & Schwarzenberg.Muenchen Wien Baltimore,1987.314
62 Harl-Hermann M.Hepatologie in klinik und praxis.Geory Thieme Verlag stuttgart New York,1989.287
7[1]Suehiro T,Yamamoto M,Yoshida K,et al. Increase of plasma proapolipoprotein A1 in patients with liver cirrhosis and its relationship to circulating high-density lipoproteins 2 and 3. Clin Chem,1993,39(1):60～65.
8[2]Mathurin P,Vidaud D,Vadaud M,et al. Quantification of apolipoprotein A1 and B messenger RNA in heavy drinker according to liver disease. Hepatology,1996,23(1):44～45.
9[3]Alessandri C,Basili S,Maurelli M,et al. Relationship between lipoprotein(a) levels in serum and some indices of protein synthesis in liver cirrhosis. Clin Chem Acta,1994,224(2):125～129.
7FLA M M SLChronic hepatitisc virus infection[J].JAMA,2003,289:2413-2417.
8Thomas T,Ginsberg H. Development of apolipoprotein B antisense molecules as a therapy for hyperlipidemia[J]. Current Atherosclerosis Reports, 2010,12( 1 ) : 58-65.
9Mauer K,Exaire JE, Stoner JA. Reduced high-density lipoprotein level is linked to worse ankle brachial index and peak oxygen uptake in postmenopausal women with peripheral arterial disease [J]. Angiology, 2010,61 (7) : 698-704.
